DNMT3A and myelodysplastic syndrome: In the follow-up of MDS patients treated with HMAs (over 70 months of follow-up), the median Progression-Free Survival (PFS) in the DNMT3A R882 mutation group was 20.3 months, which was significantly lower than the 50 months in the non-mutated group (48).